Bevacomb 5 mg/160 mg Filmdragerad tablett

국가: 스웨덴

언어: 스웨덴어

출처: Läkemedelsverket (Medical Products Agency)

유효 성분:

amlodipinbesilat; valsartan

제공처:

Teva B.V.

ATC 코드:

C09DB01

INN (International Name):

amlodipine besylate; valsartan

복용량:

5 mg/160 mg

약제 형태:

Filmdragerad tablett

구성:

valsartan 160 mg Aktiv substans; amlodipinbesilat 6,95 mg Aktiv substans

처방전 유형:

Receptbelagt

제품 요약:

Förpacknings: Blister, 7 tabletter; Blister, 14 tabletter; Blister, 28 tabletter; Blister, 30 tabletter; Blister, 56 tabletter; Blister, 60 tabletter; Blister, 90 tabletter; Blister, 98 tabletter; Blister, 280 tabletter

승인 상태:

Godkänd

승인 날짜:

2016-11-25

환자 정보 전단

PACKAGE LEAFLET: INFORMATION FOR THE USER
BEVACOMB 5 MG/80 MG FILM-COATED TABLETS
BEVACOMB 5 MG/160 MG FILM-COATED TABLETS
BEVACOMB 10 MG/160 MG FILM-COATED TABLETS
amlodipine/valsartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Bevacomb is and what it is used for
2.
What you need to know before you take Bevacomb
3.
How to take Bevacomb
4.
Possible side effects
5.
How to store Bevacomb
6.
Contents of the pack and other information
1.
WHAT BEVACOMB IS AND WHAT IT IS USED FOR
Bevacomb tablets contain two substances called amlodipine and
valsartan. Both of these substances
help to control high blood pressure.
−
Amlodipine belongs to a group of substances called “calcium channel
blockers”.
Amlodipine stops calcium from moving into the blood vessel wall which
stops the blood
vessels from tightening.
−
Valsartan belongs to a group of substances called “angiotensin-II
receptor antagonists”.
Angiotensin II is produced by the body and makes the blood vessels
tighten, thus increasing
the blood pressure. Valsartan works by blocking the effect of
angiotensin II.
This means that both of these substances help to stop the blood
vessels tightening. As a result,
the blood vessels relax and blood pressure is lowered.
Bevacomb is used to treat high blood pressure in adults whose blood
pressure is not controlled
enough with either amlodipine or valsartan on its own.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE BEVACOMB
DO NOT TAKE BEVACOMB
−
if you are allergic to amlodipine or to any other calcium c

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Bevacomb 5 mg/80 mg film-coated tablets
Bevacomb 5 mg/160 mg film-coated tablets
Bevacomb 10 mg/160 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine
besylate) and 80 mg of valsartan.
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine
besylate) and 160 mg of valsartan.
Each film-coated tablet contains 10 mg of amlodipine (as amlodipine
besylate) and 160 mg of
valsartan.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet
5mg/80mg
Yellow, 8mm round, biconvex, film-coated tablet, imprinted with
“I” on one side and “LD” on the
other side.
5mg/160mg
Yellow, 13.5 x 7mm oval, biconvex, film-coated tablet, imprinted with
“2” on one side and “LD” on
the other side.
10mg/160mg
White, 13.5 x 7mm oval, biconvex, film-coated tablet, imprinted with
“3” on one side and “LD” on
the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension.
Bevacomb is indicated in adults whose blood pressure is not adequately
controlled on amlodipine or
valsartan monotherapy.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose of Bevacomb is one tablet per day.
Bevacomb 5 mg/80 mg may be administered in patients whose blood
pressure is not adequately
controlled with amlodipine 5 mg or valsartan 80 mg alone.
Bevacomb 5 mg/160 mg may be administered in patients whose blood
pressure is not adequately
controlled with amlodipine 5 mg or valsartan 160 mg alone.
Bevacomb 10 mg/160 mg may be administered in patients whose blood
pressure is not adequately
controlled with amlodipine 10 mg or valsartan 160 mg alone or with
Bevacomb 5 mg/160 mg.
Bevacomb can be used with or without food.
Individual dose titration with the components (i.e. amlodipine and
valsartan) is recommended before
changing to the fixed dose combination. When clinically appropriate,
direct change